B. Douglas Hoey, RPh, MBA

Presenting what they believe are the problems and solutions, PCMA CEO David Marin and NCPA CEO Douglas Hoey, RPh, discuss the US drug pricing dilemma.

With insights from executives working around the clock to advance the pharmacy profession, our experts predicted what the landscape will look like following the Consolidated Appropriations Act of 2026.

Douglas Hoey, CEO of NCPA, discusses what independent pharmacies can do to handle an influx of patients and what the chain’s situation means for the pharmacy landscape.

A conversation with Douglas Hoey, RPh, MBA, CEO of NCPA, on the chain pharmacy’s announcement of a second Chapter 11 bankruptcy.

Douglas Hoey, CEO of NCPA, discusses what pharmacies can do to increase revenue and avoid shutting their doors.

A discussion with Douglas Hoey, RPh, MBA, CEO of NCPA, at AAP 2025.

At AAP 2025, Douglas Hoey, RPh, MBA, CEO of NCPA, discussed what pharmacies can do to increase revenue and avoid shutting their doors.

At AAP 2025, Douglas Hoey, CEO of NCPA, discussed the possibility of PBM reform under the new administration and his take on Optum Rx’s plans to introduce a cost-plus reimbursement model.

At the American Associated Pharmacies Annual Conference, Douglas Hoey, RPh, MBA, discussed what needs to change in the program so that it does not hurt pharmacies and patients.

A conversation with Douglas Hoey, CEO of the National Community Pharmacists Association, at the American Associated Pharmacies 2025 Annual Conference.

If CMS doesn’t reconsider its mandate, which forces independent pharmacies to go deep into a hole and lose money, many of them will close.

Policymakers have the power to get pharmacy benefit managers under control.

What one pharmacist says the AAOA Pharmacy Toolkit can do to help combat the opioid epidemic. 

The time has come for pharmacists to work on reforming the maximum allowable costs put forth by the pharmacy benefit managers